Corcept's ovarian cancer treatment under FDA review

3 hours ago 1

Corcept Therapeutics (NASDAQ:CORT) said that the U.S. FDA will review its marketing application for relacorilant, its oral therapy, for the treatment of platinum-resistant ovarian cancer.
The agency has assigned a target action date of July 11, 2026.
Corcept’s application is